177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.

We presented a promising result of radionuclide therapy using Lu-PSMA and Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. PMID: 31689280 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31689280?dopt=Abstract

Source: Clinical Prostate Cancer - November 8, 2019 Category: Cancer & Oncology Authors: Assadi M, Pirayesh E, Rekabpour SJ, Zohrabi F, Jafari E, Nabipour I, Esmaili A, Amini A, Ahmadzadehfar H Tags: Clin Nucl Med Source Type: research